The current AIs for adult women and men ages 19 and older are 90 and 120 g/day, respectively, for pregnancy, 90 g/day, and for lactation, 90 g/day
old women
Semaglutide, a GLP-1 receptor agonist originally designed for type 2 diabetes, has demonstrated significant effects on lipid metabolism beyond weight reduction
Finally, disproportionality analysis based on FAERS showed neither causality nor quantified risk due to the lack of pharmacological mechanism study but only showed an evaluation of the signal strength, which was just a statistical association ( Conclusion We explored the relationship between GLP-1 RAs and gastrointestinal AEs from various perspectives and quantified the potential risks based on a comprehensive and systematic retrospective analysis of the FAERS database
physician or nurse practitioner who conducts a proper medical evaluation
maintaining the same weights week over week is not enough to signal preservation